Naltrexone salt selection for enhanced transdermal permeation through microneedle-treated skin

Journal of Pharmaceutical Sciences

Volumn 101, Issue 8, 2012, Pages 2777-2786

  Milewski, Mikolaj ^a   Pinninti, Raghotham R ^a   Stinchcomb, Audra L ^b  

^a University of Kentucky   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

Author keywords

Diffusion; In vitro models; Microneedles; Naltrexone; Permeability; Salts; Skin; Solubility; Transdermal drug delivery

Indexed keywords

NALTREXONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CONTROLLED STUDY; CRYSTAL; CUTANEOUS PARAMETERS; DIFFERENTIAL SCANNING CALORIMETRY; DIFFUSION; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG TRANSPORT; GUINEA PIG; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; MICRONEEDLE; NEEDLE; NONHUMAN; PH; PROTON NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; SKIN; SKIN COLOR; SKIN IRRITATION; SKIN WATER LOSS; SOLUBILITY; STATISTICAL ANALYSIS; THERMAL ANALYSIS; VISCOSITY;

EID: 84862884589     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23189     Document Type: Article

References (23)

1. Harding Clive R. 2004. The stratum corneum: Structure and function in health and disease. Dermatol Ther 17(Suppl 1):6-15.
2. Madison KC. 2003. Barrier function of the skin: "La raison d'etre" of the epidermis. J Invest Dermatol 121(2):231-241.
3. Prausnitz MR, Mitragotri S, Langer R. 2004. Current status and future potential of transdermal drug delivery. Nat Rev Drug Discov 3(2):115-124.
4. Prausnitz MR, Langer R. 2008. Transdermal drug delivery. Nat Biotechnol 26(11):1261-1268.
5. Arora A, Prausnitz MR, Mitragotri S. 2008. Micro-scale devices for transdermal drug delivery. Int J Pharm 364(2):227-236.
6. Haq MI, Smith E, John DN, Kalavala M, Edwards C, Anstey A, Morrissey A, Birchall JC. 2009. Clinical administration of microneedles: Skin puncture, pain and sensation. Biomed Microdevices 11(1):35-47.
7. Kaushik S, Hord AH, Denson DD, McAllister DV, Smitra S, Allen MG, Prausnitz MR. 2001. Lack of pain associated with microfabricated microneedles. Anesth Analg 92(2):502-504.
8. Gill HS, Denson DD, Burris BA, Prausnitz MR. 2008. Effect of microneedle design on pain in human volunteers. Clin J Pain 24(7):585-594.
9. Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP. 1997. Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54(8):737-742.
10. Paudel KS, Nalluri BN, Hammell DC, Valiveti S, Kiptoo P, Hamad MO, Crooks PA, Stinchcomb AL. 2005. Transdermal delivery of naltrexone and its active metabolite 6-beta-naltrexol in human skin in vitro and guinea pigs in vivo. J Pharm Sci 94(9):1965-1975.
11. Banks SL, Pinninti RR, Gill HS, Crooks PA, Prausnitz MR, Stinchcomb AL. 2008. Flux across microneedle-treated skin is increased by increasing charge of naltrexone and naltrexol in vitro. Pharm Res 25(7):1677-1685.
12. Milewski M, Yerramreddy TR, Ghosh P, Crooks PA, Stinchcomb AL. 2010. In vitro permeation of a PEGylated naltrexone prodrug across microneedle-treated skin. J Control Release 146(1):37-44.
13. Banks SL, Paudel KS, Pinninti RR, Gill HS, Crooks PA, Brogden NK, Prausnitz MR, Stinchcomb AL. 2010. Transdermal delivery of naltrexol and skin permeability lifetime after microneedle treatment in hairless guinea pigs. J Pharm Sci 99(7):3072-3080.
14. Wermeling DP, Banks SL, Hudson DA, Gill HS, Gupta J, Prausnitz MR, Stinchcomb AL. 2008. Microneedles permit transdermal delivery of a skin-impermeant medication to humans. Proc Natl Acad Sci U S A 105(6):2058-2063.
15. Gill HS, Prausnitz MR. 2007. Coated microneedles for transdermal delivery. In J. Control Release 117 (2): 227-237.
16. Hussain MA, Koval CA, Myers MJ, Shami EG, Shefter E. 1987. Improvement of the oral bioavailability of naltrexone in dogs: A prodrug approach. J Pharm Sci 76(5):356-358.
17. Milewski M, Stinchcomb AL. 2010. Vehicle composition influence on the microneedle-enhanced transdermal flux of naltrexone hydrochloride. Pharm Res 28(1):124-134.
18. Kaufman JJ, Semo NM, Koski WS. 1975. Microelectrometric titration measurement of the pKa's and partition and drug distribution coefficients of narcotics and narcotic antagonists and their pH and temperature dependence. J Med Chem 18(7):647-655.
19. Serajuddin ATM. 2007. Salt formation to improve drug solubility. Adv Drug Deliv Rev 59(7):603-616.
20. Kretsos K, Miller MA, Zamora-Estrada G, Kasting GB. 2008. Partitioning, diffusivity and clearance of skin permeants in mammalian dermis. Int J Pharm 346(1-2):64-79.
21. Flynn GL. 1990. Cutaneous and transdermal delivery: processes and systems of delivery. In Modern pharmaceutics; Banker GS, Rhodes CT, Eds. 2nd ed. New York: Marcel Dekker. pp 239-298.
22. FDA. 2009. Alpha hydroxy acids in cosmetics. Silver Spring, Maryland: FDA
23. Andersen F, Hedegaard K, Fullerton A, Petersen TK, Bindslev-Jensen C, Andersen KE. 2006. The hairless guinea-pig as a model for treatment of acute irritation in humans. Skin Res Technol 12(3):183-189.